Joel Greenblatt Biotechnology

Gotham Asset Management, LLC

$9.41 Billion
Q3 2024

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade
UTHR United Therapeutics Corp	$16.4B	$18.7 Million 0.2% of portfolio	52,058	Q3 2024 Added 9.38%
VRTX Vertex Pharmaceuticals Inc	$105B	$12.6 Million 0.13% of portfolio	27,133	Q3 2024 Added 9.8%
EXEL Exelixis, Inc.	$10.9B	$7.82 Million 0.08% of portfolio	301,480	Q3 2024 Added 19.07%
REGN Regeneron Pharmaceuticals, Inc.	$76.6B	$5.92 Million 0.06% of portfolio	5,627	Q3 2024 Reduced 1.28%
ALNY Alnylam Pharmaceuticals, Inc.	$29.9B	$4.83 Million 0.05% of portfolio	17,575	Q3 2024 Added 32.77%
INCY Incyte Corp	$15.6B	$4.32 Million 0.05% of portfolio	65,392	Q3 2024 Reduced 18.4%
MRVI Maravai Lifesciences Holdings, Inc.	$701M	$3.89 Million 0.04% of portfolio	467,848	Q3 2024 Reduced 2.05%
ADMA Adma Biologics, Inc.	$3.42B	$3.29 Million 0.03% of portfolio	164,565	Q3 2024 Added 110.58%
TGTX Tg Therapeutics, Inc.	$4.67B	$2.7 Million 0.03% of portfolio	115,282	Q3 2024 Added 57.26%
HRMY Harmony Biosciences Holdings, Inc.	$2.02B	$2.67 Million 0.03% of portfolio	66,722	Q3 2024 Reduced 21.51%
HALO Halozyme Therapeutics, Inc.	$6.62B	$2.48 Million 0.03% of portfolio	43,262	Q3 2024 Added 52.46%
JAZZ Jazz Pharmaceuticals PLC	$7.76B	$2.34 Million 0.02% of portfolio	21,033	Q3 2024 Added 250.55%
BMRN Biomarin Pharmaceutical Inc	$12.4B	$1.64 Million 0.02% of portfolio	23,395	Q3 2024 New
ACLX Arcellx, Inc.	$3.4B	$1.09 Million 0.01% of portfolio	13,001	Q3 2024 Added 37.58%
CORT Corcept Therapeutics Inc	$5.59B	$861,000 0.01% of portfolio	18,614	Q3 2024 Reduced 25.41%
CPRX Catalyst Pharmaceuticals, Inc.	$2.22B	$718,000 0.01% of portfolio	36,141	Q3 2024 Added 7.25%
INVA Innoviva, Inc.	$1.24B	$617,000 0.01% of portfolio	31,987	Q3 2024 Added 4.99%
GANX Gain Therapeutics, Inc.	$18.9M	$595,000 0.01% of portfolio	334,592	Q3 2024 New
VCEL Vericel Corp	$2.7B	$576,000 0.01% of portfolio	13,654	Q2 2024 Reduced 0.01%
IOVA Iovance Biotherapeutics, Inc.	$1.18B	$572,000 0.01% of portfolio	61,009	Q3 2024 New
VCYT Veracyte, Inc.	$2.95B	$561,000 0.01% of portfolio	16,508	Q3 2024 Added 9.61%
ACAD Acadia Pharmaceuticals Inc	$2.76B	$549,000 0.01% of portfolio	35,726	Q3 2024 Added 16.76%
RYTM Rhythm Pharmaceuticals, Inc.	$3.11B	$496,000 0.01% of portfolio	9,471	Q3 2024 Reduced 24.99%
ROIV Roivant Sciences Ltd.	$8.45B	$450,000 0.0% of portfolio	39,027	Q3 2024 Reduced 1.29%
SMMT Summit Therapeutics Inc.	$3.82B	$348,000 0.0% of portfolio	15,908	Q3 2024 Reduced 18.42%
AUPH Aurinia Pharmaceuticals Inc.	$1.27B	$303,000 0.0% of portfolio	41,341	Q3 2024 Added 2.6%
BCRX Biocryst Pharmaceuticals Inc	$1.43B	$295,000 0.0% of portfolio	38,893	Q3 2024 New
MNKD Mannkind Corp	$1.73B	$272,000 0.0% of portfolio	43,349	Q3 2024 Added 1.33%
IONS Ionis Pharmaceuticals Inc	$5.19B	$250,000 0.0% of portfolio	6,262	Q2 2024 Reduced 7.72%
ARDX Ardelyx, Inc.	$742M	$171,000 0.0% of portfolio	24,905	Q3 2024 Reduced 85.73%
VIGL Vigil Neuroscience, Inc.	$46.1M	$20,000 0.0% of portfolio	5,933	Q3 2024 New

Shares Options

Joel Greenblatt

Joel Greenblatt is the founder and managing partner of Gotham Asset Management, a successful investment firm that focuses on value investing. Greenblatt is known for his expertise in value investing and his contrarian approach to investing. He has generated strong returns for his clients over the long term.

Track Joel Greenblatt's portfolio

Track Joel Greenblatt's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Gotham Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Gotham Asset Management, LLC and Joel Greenblatt with notifications on news.

Account